TY - JOUR
T1 - Retroperitoneal sarcomas
T2 - Combined modality treatment approaches
AU - Pisters, Peter W.T.
AU - O'Sullivan, Brian
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - Retroperitoneal soft tissue sarcomas are rare tumors estimated to account for 15%of all patients with soft tissue sarcoma seen in referral populations. The standard of care for patients with localized, resectable retroperitoneal sarcomas is surgical resection with gross and microscopically negative margins. However, owing to the large size and locally advanced nature of these tumors, this goal is difficult to achieve in most patients. As a result, the disease is characterized by a high propensity for local recurrence and a grade-specific risk for distant metastasis. Over the past decade, there has been considerable research into combined modality treatment of these tumors. The present report outlines current concepts relating to the diagnosis, staging, and management of retroperitoneal sarcomas. Emphasis is placed on evolving combined modality treatment approaches and current investigational strategies.
AB - Retroperitoneal soft tissue sarcomas are rare tumors estimated to account for 15%of all patients with soft tissue sarcoma seen in referral populations. The standard of care for patients with localized, resectable retroperitoneal sarcomas is surgical resection with gross and microscopically negative margins. However, owing to the large size and locally advanced nature of these tumors, this goal is difficult to achieve in most patients. As a result, the disease is characterized by a high propensity for local recurrence and a grade-specific risk for distant metastasis. Over the past decade, there has been considerable research into combined modality treatment of these tumors. The present report outlines current concepts relating to the diagnosis, staging, and management of retroperitoneal sarcomas. Emphasis is placed on evolving combined modality treatment approaches and current investigational strategies.
UR - http://www.scopus.com/inward/record.url?scp=0035988122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035988122&partnerID=8YFLogxK
U2 - 10.1097/00001622-200207000-00006
DO - 10.1097/00001622-200207000-00006
M3 - Review article
C2 - 12130924
AN - SCOPUS:0035988122
SN - 1040-8746
VL - 14
SP - 400
EP - 405
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 4
ER -